Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat antibiotic-resistant and difficult-to-treat bacterial infections. With a focus on addressing the global antibiotic resistance crisis, Armata leverages its proprietary bacteriophage-based technology to develop high-impact, best-in-class phage therapeutics. The company operates from a 56,000 square foot facility in Los Angeles, California, equipped for phage product development from bench to clinic. Armata's team of microbiologists and scientists work on discovering natural phages and enhancing them through synthetic biology and engineering to create tailored drug products for clinical trials.
Armata Pharmaceuticals, Inc.
5005 McConnell Ave, Los Angeles, CA 90066
What We Do
Development of pathogen-specific bacteriophage therapeutics for treating antibiotic-resistant bacterial infections.
Utilizing synthetic biology tools to engineer natural phages for improved pharmacological properties and antimicrobial activity.
A therapeutic phage cocktail targeting Pseudomonas aeruginosa for treating serious respiratory infections, particularly in cystic fibrosis and non-cystic fibrosis bronchiectasis patients.
A biologic product candidate comprising natural lytic phages targeting Staphylococcus aureus, including drug-resistant isolates, for treating bacteremia.
Biologics
Regenerative Medicine
Drugs
Key People
Chief Executive Officer
Chief Business Officer
Senior Vice President of Finance
Vice President of Operations
Vice President of Quality
Regulatory Strategy and Operations
Funded Projects
Development of a Novel Bacteriophage Therapeutic for Targeted Treatment of Staphylococcus aureus Bacteremia, Including Drug Resistant Forms.
Staphylococcus aureus infection is a major military health issue. Military personnel, including those on land and at sea, are at heightened risk of infection because the operational environment often involves close quarters and shared equipment for prolonged periods of time. AP-SA02, a novel bacteriophage therapeutic, is being developed by Armata Pharmaceuticals to treat military and civilian patients with S. aureus bacteremia.